Oxford Biomedica plc (LON:OXB) Given Consensus Rating of “Moderate Buy” by Brokerages

Oxford Biomedica plc (LON:OXB) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is GBX 600.04.

Several equities research analysts have recently issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 8.27 price target on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Royal Bank Of Canada cut their price objective on Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating for the company in a research report on Wednesday, June 24th.

Oxford Biomedica Stock Performance

Shares of OXB opened at GBX 643.06 on Tuesday. The company has a market capitalization of £778.34 million, a PE ratio of -23.89 and a beta of 1.12. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. Oxford Biomedica has a one year low of GBX 350.50 and a one year high of GBX 952. The company’s fifty day moving average price is GBX 615.69 and its 200 day moving average price is GBX 663.77.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.